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Of Mice and MEN: What Transgenic Minireview
Models Tell Us about Hypothalamic
Control of Energy Balance
agouti-related protein (AGRP or ART) (Barsh 1999; Elm-
quist et al., 1999), the natural MC4 receptor antagonist
of a-MSH. Transgenic mice that overexpress AGRP, like
mice with a targeted deletion of the MC4 receptor, de-
velop an obesity syndrome that recapitulates several
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characteristics of the agouti mutation. The importanceNew York, New York 10029
of the melanocortin pathway as a critical regulator of
energy balance has been reinforced by the finding that
POMC mutations can cause obesity, adrenal insuffi-The hypothalamus plays a key role in the regulation
ciency, and alterations in hair pigmentation in mice (Yas-of food intake and energy expenditure, demonstrated
wen et al., 1999) and humans (Krude et al., 1998) andthrough the effects that discrete lesions within this re-
several reports that MC4-R mutations are associatedgion of the brain have on appetite and body weight.
with dominantly inherited human obesity (Barsh, 1999).Lesions in the lateral hypothalamus (LHA) or ªfeeding
Despite overwhelming genetic evidence in mice and hu-centerº lead to decreased food intake and weight loss,
mans that a-MSH is a critical satiety-inducing peptide,primarily by eliminating the neurons that promote feed-
the response to central injection of a-MSH itself is noting through their projections elsewhere in the CNS (i.e.,
particularly robust, highlighting a subtle difference be-orexigenic pathways; Elmquist et al., 1999). Lesions of
tween pharmacological and genetic findings.the ventromedial and arcuate nuclei or ªsatiety centerº
Further characterization of the melanocortin pathwayproduce hyperphagia and obesity, most likely by de-
has been accomplished through the analysis of genesstroying the leptin-responsive neurons that decrease
that suppress the agouti phenotype. Mutations at thefeeding via anorexigenic projections to the LHA, para-
mahogany locus, when homozygous, can suppress theventricular nucleus (PVN), and central autonomic sites.
effects of Ay on coat color and body weight. RecentOver the past 5 years, analysis of a diverse group of
positional cloning reveals that the mahogany gene en-transgenic and naturally occurring mouse mutants has
codes a single transmembrane-spanning protein that issubstantially increased our understanding of the patho-
structurally similar to cell surface proteoglycans. Sincephysiology of obesity, a relatively common disturbance
the mahogany mutation does not suppress the obeseof energy balance. A picture of intricate signaling within
phenotype of the MC4-R mutant, nor that of severalthe brain as well as complex hormonal communication
other obese mouse models such as db/db, tub, andbetween metabolically active peripheral tissues and the
Cpefat, it would appear that the mahogany protein func-nervous system is emerging, but in the process, seem-
tions in the pathway downstream of a-MSH but up-ingly contradictory genetic and pharmacological data
stream of MC4-R, perhaps as a signaling or low-affinityare mounting (compare Figures 1A and 1B). What do
receptor for the agouti protein (Figure 1A; Gunn et al.,transgenic models really tell us about the brain and the
1999; Nagle et al., 1999).regulation of energy homeostasis, and can these studies
Products of the ob and db genesÐleptin and its re-be reconciled with pharmacological and physiological
ceptor, respectivelyÐare cornerstones of the other ma-analyses?
jor pathway that suppresses appetite in mammals byGene Targeting of Anorexigenic Pathways:
relaying the metabolic state of peripheral adipose tis-
Mutated and Not Satiated
sues, the primary site of leptin synthesis, to the hypothal-
Pharmacological and genetic studies indicate that the
amus. Pharmacological and genetic studies are in gen-
melanocortin system makes a critical contribution to the eral agreement that leptin pathways play a critical role
regulation of many of the central responses to satiety in the regulation of energy balance (Figure 1). Mice that
signals (Figure 1). Identification of the agouti signaling fail to synthesize leptin (ob/ob) or those that express
protein, ectopically overexpressed in one of the most abnormal hypothalamic leptin receptors (db/db) de-
extensively studied obese mouse models, Ay/a agouti, velop early onset obesity, increased food intake, re-
provided the impetus for future biochemical and genetic duced metabolic rate, and infertility (Elmquist et al.,
investigation of energy balance (Barsh, 1999). The agouti 1999). Peripheral or central administration of the 16 kDa
product antagonizes the action of a-MSH, a satiety- leptin protein to ob/ob mice rescues reproductive func-
inducing neuropeptide that is cleaved from the proopio- tion and results in weight loss through an increase in
melanocortin (POMC) precursor, by competing for its metabolic rate and locomotor activity and a decrease in
binding to the G protein±coupled melanocortin 4 recep- feeding. The specific neuronal pathways that transduce
tor (MC4-R). The result is a maturity onset obesity syn- the leptin signal, initiated by binding to receptors in
drome that is associated with hyperphagia, hyperinsu- the hypothalamic nuclei that cluster around the median
linemia, and hyperglycemia. The finding that agouti eminence, have been functionally mapped by analyzing
functions in the hypothalamus, a tissue in which it is not ob/ob mice that are additionally mutated in other neuro-
normally synthesized, stimulated the search for closely peptide-encoding genes and through the use of probes
related proteins, culminating in the identification of the to rapidly activated components of the leptin signaling
cascade such as suppressor of cytokine signaling 3
(SOCS-3) (Elmquist et al., 1999). Although not a common³ To whom correspondence should be addressed (e-mail: salton@
neuro.mssm.edu). cause of obesity, congenital defects in leptin signaling
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Figure 1. Models, One Based on Genetic and the Other on Pharmacological Data, of the Hypothalamic Pathways that Regulate Energy Balance
Two models are presented, one consistent with genetic (A) and the other with pharmacological (B) data. The caliber of the arrows is proportionate
to the impact that the anorexigenic (red) or orexigenic (green) pathways have on feeding and/or metabolism. Pathways that appear to have
a lesser impact on energy metabolism have been left out for the sake of simplicity. The melanocortin, MCH, and leptin pathways have been
implicated by genetic and pharmacological studies as being critical regulators of energy homeostasis and so are depicted in both panels.
Major contributions of NPY, orexin, b-endorphin, CRF, and GLP-1 to the control of energy balance are not supported by genetic analyses,
and so these pathways are shown only in (B). Abbreviations: AGRP, agouti-related peptide; a-MSH, a-melanocyte-stimulating hormone; ARC,
arcuate nucleus; b-end, b-endorphin; CRF, corticotropin-releasing factor; CRF-R1, CRF receptor 1; DMH, dorsomedial hypothalamus; GLP-1,
glucagon-like peptide 1; GLP-1R, GLP-1 receptor, Lep-R, leptin receptor; LHA, lateral hypothalamic area; mah, mahogany; MC4-R, melanocortin
4 receptor; MCH, melanin-concentrating hormone; NPY, neuropeptide Y; ORX, orexin/hypocretin; PVN, paraventricular nucleus; VMH, ventrome-
dial hypothalamus; Y1, NPY receptor 1; Y5, NPY receptor 5.
due to mutations in human leptin or leptin receptor orexigenic pathways in the regulation of energy balance
(Figures 1A and 1B, green arrows). Feeding is stimulatedgenes have been shown to cause early onset morbid
obesity and pituitary dysfunction (Elmquist et al., 1999). by the central administration of a number of neuro-
peptides including neuropeptide Y (NPY), melanin-con-What about other pharmacologically defined anorexi-
genic peptides? Alterations in feeding and metabolism centrating hormone (MCH), the orexins/hypocretins,
galanin, and b-endorphin. Gene targeting of potent ore-do not appear to result from genetic disruption of two
other anorexigenic pathways (compare red arrows in xigenic peptides would consequently be expected to
result in decreased feeding and possibly weight loss,Figures 1A and 1B). There is considerable evidence that
central injection of corticotropin-releasing factor (CRF), yet thus far only targeted mutation of the Mch gene
has been shown to result in hypophagia, reduced bodythe primary hypothalamic hormone that stimulates re-
lease of pituitary adrenocorticotrophic hormone (ACTH), weight, and an inappropriately increased rate of metab-
olism (Figure 1; Shimada et al., 1998). Analysis of MCHcan suppress food intake. Yet neither selective gene
targeting of CRF (Muglia et al., 1995) nor the CRF recep- mutant mice indicates that MCH is a critical effector of
energy balance downstream of the leptin and melano-tor 1 (Smith et al., 1998) has been reported to result in
changes in food intake, body weight, or fertility, despite cortin systems. MCH and a-MSH are functional but
not pharmacological antagonists, most notably in thedramatic effects on adrenal maturation. Furthermore,
intraventricular administration of the glucagon-like pep- salmon where they regulate skin color by controlling
pigment dispersion in melanosomes but also in thetide 1 (GLP-1) inhibits food intake in fasted rats, while
targeted mutation of the GLP-1 receptor in mice does mammalian brain where they regulate feeding. MCH has
been localized in magnocellular neurons of the lateralnot alter feeding behavior (Scrocchi et al., 1996). There-
fore, either CRF, the CRF type 1 receptor, and the GLP-1 hypothalamus and zona incerta and acts via a recently
identified G protein±coupled receptor (Chambers et al.,receptor play redundant roles in the control of feeding
behavior and metabolism, and their absence can be 1999; Saito et al., 1999). Future targeted mutation of the
MCH receptor gene may therefore provide additionalcompensated for, or central injection activates these
pathways in a nonphysiological manner. insight into the role that the MCH system plays in the
control of feeding and metabolism.Gene Targeting of Orexigenic Pathways:
Mutation without Representation Until the description of lean MCH mutant mice, redun-
dancy of hypothalamic orexigenic neuropeptide expres-Genetic and pharmacological analyses lead to very dis-
parate views of the overall importance of several major sion was felt to be responsible for the lack of effect that
Minireview
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gene targeting of Npy had on feeding and body weight. characterized and are therefore not shown in Figure 1,
genetic approaches can identify intracellular proteins,Despite the wealth of data indicating that centrally ad-
ministered NPY is a potent stimulator of feeding, the such as processing enzymes or signaling molecules, as
regulators of energy balance in the absence of priorbulk of the genetic data suggests that NPY is not an
essential regulator of energy balance (Figure 1A versus pharmacological or physiological data.
Defined purely on the basis of genetic analysis, au-1B). Mice with gene-targeted inactivation of either NPY
Y1 (Kushi et al., 1998) or Y5 (Marsh et al., 1998) receptors tosomal recessive mutations in fat (Cpefat) and tubby
mice are associated with maturity onset weight gain.are paradoxically obese with increased weight and adi-
posity, suggesting that in mice, neither is a critical physi- The alternatively spliced Tub transcript is expressed
primarily by neurons in the cerebral cortex, hippocam-ological feeding receptor. Homozygous NPY mutant
mice are metabolically indistinguishable from controls, pus, hypothalamus, inner ear, and retina and encodes
a member of a family of related proteins that until re-eat normally, and respond to fasting and to chemical-
and diet-induced obesity as do wild-type mice (Palmiter cently had no known function. The tubby phenotype,
characterized by late onset obesity, insulin resistance,et al., 1998). In addition, the genetic crossing of NPY
mutant mice and two different obese strains, Ay/a agouti infertility, and progressive cochlear and retinal degener-
ation, is similar to that found in two human syndromes,and a transgenic mouse model that lacks brown adipose
tissue (BAT), yields double mutants that are indistin- Alstrom's and Bardet/Biedl. Recent structural and func-
tional studies indicate that Tub is a transcription factor,guishable from parental agouti or BAT transgenic mice,
respectively. Interestingly, abnormalities due to the fail- suggesting that future identification of the genes that
are regulated by Tub signaling might provide importanture to synthesize NPY do become apparent when homo-
zygous Npy2/Npy2, ob/ob mice are analyzed. These new insight into obesity and diabetes (Boggon et al.,
1999, and references therein).double mutants are less obese than ob/ob mice but
still respond vigorously to the satiety-inducing effect of The Cpefat mouse has a mutation in the gene encoding
the enzyme carboxypeptidase E (Cpe) that trims C-ter-administered leptin, suggesting that the hyperphagia,
reduced metabolic rate, and endocrine abnormalities minal paired basic residues from prohormones such as
proinsulin or the MCH and neurotensin precursors, andthat result from leptin deficiency are mediated in part
through NPYergic pathways. Overall, however, pharma- the obese, hyperglycemic phenotype of these mice
therefore appears to result from abnormal neuropeptidecological and genetic analyses lead to widely different
estimates of the importance of NPY in the regulation of processing. Although an inherited defect in human CPE
has not been described, obesity that is phenotypicallyfeeding.
Injection of b-endorphin, an endogenous opioid pep- similar to that observed in Cpefat mice has been reported
to result from a mutation in another processing enzyme,tide that is processed from the POMC precursor, and
hypocretin/orexin A or B into the hypothalamus stimu- prohormone convertase 1 (PC1) (Jackson et al., 1997).
Genetic analysis therefore suggests that defects in neu-lates feeding (Figure 1B). However, introduction of a
translation stop signal through targeted mutagenesis of ropeptide processing enzymes and intracellular signal-
ing molecules can cause obesity.the POMC gene in ES cells generates mice with a selec-
tive deficiency in b-endorphin but no phenotypic alter- Analysis of lean or anorexic mice should also offer
mechanistic insight into obesity, cachexia, and the hy-ations in feeding behavior or hypothalamic±pituitary±
gonadal (HPG) axis function (Rubinstein et al., 1996). pothalamic control of energy balance. Lean mice with
a null mutation of VGF, a secreted neuronal and neuroen-Recent description of orexin knockout mice that mani-
fest a striking disorder of sleep regulation, and the map- docrine polypeptide, manifest increased metabolic and
locomotor activity as well as dramatic alterations in hy-ping of a causative mutation for canine narcolepsy to
the hypocretin/orexin receptor 2 gene, together demon- pothalamic NPY, AGRP, and POMC gene expression
and circulating leptin, glucose, and corticosterone levelsstrate that disruption of orexin signaling results in a
profound behavioral phenotype that apparently does (Hahm et al., 1999). Analysis of VGF knockout mice sup-
ports a role for VGF as a downstream effector in thenot extend to dramatic alterations in feeding (Siegel,
1999). Lack of a clear metabolic phenotype may there- leptin and melanocortin pathways. That VGF synthesis
is also regulated by neurotrophins may be indicative offore be due to the redundancy of orexigenic pathways,
yet both feeding and metabolic rate are compromised an unexplored contribution of these growth factors to
the control of energy homeostasis.in MCH mutant mice. The MCH system may be the ex-
ception rather than the rule, and the lean, hypophagic Future Directions
Although Jack Sprat could eat no fat and his wife couldphenotype of MCH-deficient mice may actually be the
result of an increase in a-MSH signaling, a pathway eat no lean, hypothalamic control of food intake is hardly
this straightforward, nor seemingly is the pursuit of awhich appears to be extremely sensitive to genetic ma-
nipulation. Alternatively, regulation of feeding by several unified model that explains how feeding and metabolism
are regulated. Persuasive pharmacological and physio-of these orexigenic neuropeptides may not be as physio-
logically relevant as pharmacological studies have indi- logical analyses indicate that many gene products con-
tribute to the maintenance of energy homeostasis, andcated.
New Insights from Genetic Models of Anorexia although mutations in several of these lead to profound
alterations in feeding, body weight, and metabolism,and Obesity
Targeted mutagenesis and the cloning of candidate gene targeting of the remainder have not, leading to
very different models of the key regulatory pathways.genes from mutant mice are powerful methods to iden-
tify neuronal polypeptides that regulate energy homeo- Compensatory alterations in the synthesis of function-
ally related proteins are often felt to be responsible forstasis. Although the specific pathways that are affected
by several of these mutations have not yet been fully the lack of phenotypic changes that are observed in
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Smith, G.W., Aubry, J.M., Dellu, F., Contarino, A., Bilezikjian, L.M.,mutant mice. Mice that fail to synthesize neuropeptides
Gold, L.H., Chen, R., Marchuk, Y., Hauser, C., Bentley, C.A., et al.such as CRF, NPY, b-endorphin, or hypocretin/orexin
(1998). Neuron 20, 1093±1102.may not have abnormal metabolic phenotypes but do
Yaswen, L., Diehl, N., Brennan, M.B., and Hochgeschwender, U.have other significant physiological problems, sug-
(1999). Nat. Med. 5, 1066±1070.
gesting either that compensation is incomplete or alter-
natively that these neuropeptides make relatively minor
contributions to the regulation of energy homeostasis.
Analysis of mutant mice also suggests that orexigenic
pathways are more redundant than satiety pathways,
since, for example, mutations of individual components
of the a-MSH pathway invariably affect energy balance,
whereas mutations of NPY, b-endorphin, or hypocretin/
orexin do not. More refined genetic analyses that utilize
tissue-specific or inducible gene knockouts may allow
these issues of compensation and redundancy to be
more directly assessed. Despite the identification of a
number of genetic mutations that affect energy homeo-
stasis, human obesity and anorexia at this time appear
to be overwhelmingly idiopathic, stimulating the search
for novel regulators of energy balance. As additional
mutant mice are generated and new therapeutic targets
identified, the future challenge will be to integrate ge-
netic and physiological data into a coherent model of
energy homeostasis.
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